(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the Society of Urologic Oncology (SUO) Session. Dr. Bernard ...

Johnson & Johnson announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200-an intravesical gemcitabine ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Long-term data from QUILT-3.032 showed that NAI plus BCG shows sustained responses in BCG-unresponsive bladder cancer with 84 ...

A new study published in the International Journal of Urology showed that patients with muscle-invasive bladder cancer (MIBC) ...

PRINCETON, NJ, USA I April 26, 2025 I UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions ...

Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain ...

Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer ...

Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating ...